IQV vs. RDY: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at IQV and RDY, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
IQV is a standard domestic listing, while RDY trades as an American Depositary Receipt (ADR), offering U.S. investors access to its foreign-listed shares.
| Symbol | IQV | RDY |
|---|---|---|
| Company Name | IQVIA Holdings Inc. | Dr. Reddy's Laboratories Limited |
| Country | United States | India |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Life Sciences Tools & Services | Pharmaceuticals |
| Market Capitalization | 32.65 billion USD | 12.18 billion USD |
| Exchange | NYSE | NYSE |
| Listing Date | May 9, 2013 | April 11, 2001 |
| Security Type | Common Stock | ADR |
Historical Performance
This chart compares the performance of IQV and RDY by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | IQV | RDY |
|---|---|---|
| 5-Day Price Return | 1.39% | 1.16% |
| 13-Week Price Return | 33.79% | 3.95% |
| 26-Week Price Return | -2.05% | 4.99% |
| 52-Week Price Return | -21.01% | -9.49% |
| Month-to-Date Return | 3.33% | 0.83% |
| Year-to-Date Return | -2.27% | -7.88% |
| 10-Day Avg. Volume | 1.14M | 1.40M |
| 3-Month Avg. Volume | 2.21M | 1.68M |
| 3-Month Volatility | 45.60% | 19.60% |
| Beta | 1.34 | 0.68 |
Profitability
Return on Equity (TTM)
IQV
19.96%
Life Sciences Tools & Services Industry
- Max
- 19.96%
- Q3
- 11.55%
- Median
- 6.22%
- Q1
- 3.86%
- Min
- -6.95%
In the upper quartile for the Life Sciences Tools & Services industry, IQV’s Return on Equity of 19.96% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
RDY
8.86%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
RDY’s Return on Equity of 8.86% is on par with the norm for the Pharmaceuticals industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
IQV
7.88%
Life Sciences Tools & Services Industry
- Max
- 27.28%
- Q3
- 16.17%
- Median
- 7.24%
- Q1
- 3.00%
- Min
- -3.05%
IQV’s Net Profit Margin of 7.88% is aligned with the median group of its peers in the Life Sciences Tools & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
RDY
16.95%
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
RDY’s Net Profit Margin of 16.95% is aligned with the median group of its peers in the Pharmaceuticals industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin (TTM)
IQV
13.85%
Life Sciences Tools & Services Industry
- Max
- 33.15%
- Q3
- 19.34%
- Median
- 13.02%
- Q1
- 8.05%
- Min
- -4.38%
IQV’s Operating Profit Margin of 13.85% is around the midpoint for the Life Sciences Tools & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
RDY
20.17%
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
RDY’s Operating Profit Margin of 20.17% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | IQV | RDY |
|---|---|---|
| Return on Equity (TTM) | 19.96% | 8.86% |
| Return on Assets (TTM) | 4.50% | 5.93% |
| Net Profit Margin (TTM) | 7.88% | 16.95% |
| Operating Profit Margin (TTM) | 13.85% | 20.17% |
| Gross Profit Margin (TTM) | 34.25% | 68.36% |
Financial Strength
Current Ratio (MRQ)
IQV
0.84
Life Sciences Tools & Services Industry
- Max
- 4.76
- Q3
- 2.77
- Median
- 1.85
- Q1
- 1.40
- Min
- 0.43
IQV’s Current Ratio of 0.84 falls into the lower quartile for the Life Sciences Tools & Services industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
RDY
1.92
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
RDY’s Current Ratio of 1.92 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
IQV
2.68
Life Sciences Tools & Services Industry
- Max
- 1.75
- Q3
- 0.83
- Median
- 0.41
- Q1
- 0.18
- Min
- 0.00
With a Debt-to-Equity Ratio of 2.68, IQV operates with exceptionally high leverage compared to the Life Sciences Tools & Services industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
RDY
0.14
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
RDY’s Debt-to-Equity Ratio of 0.14 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
IQV
3.68
Life Sciences Tools & Services Industry
- Max
- 29.61
- Q3
- 23.24
- Median
- 6.07
- Q1
- 2.18
- Min
- -14.08
IQV’s Interest Coverage Ratio of 3.68 is positioned comfortably within the norm for the Life Sciences Tools & Services industry, indicating a standard and healthy capacity to cover its interest payments.
RDY
13.50
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
RDY’s Interest Coverage Ratio of 13.50 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | IQV | RDY |
|---|---|---|
| Current Ratio (MRQ) | 0.84 | 1.92 |
| Quick Ratio (MRQ) | 0.81 | 1.37 |
| Debt-to-Equity Ratio (MRQ) | 2.68 | 0.14 |
| Interest Coverage Ratio (TTM) | 3.68 | 13.50 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
IQV
0.00%
Life Sciences Tools & Services Industry
- Max
- 1.80%
- Q3
- 0.78%
- Median
- 0.37%
- Q1
- 0.00%
- Min
- 0.00%
IQV currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
RDY
0.64%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
RDY’s Dividend Yield of 0.64% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
IQV
0.00%
Life Sciences Tools & Services Industry
- Max
- 156.00%
- Q3
- 65.73%
- Median
- 23.81%
- Q1
- 0.00%
- Min
- 0.00%
IQV has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
RDY
53.05%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
RDY’s Dividend Payout Ratio of 53.05% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | IQV | RDY |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.64% |
| Dividend Payout Ratio (TTM) | 0.00% | 53.05% |
Valuation
Price-to-Earnings Ratio (TTM)
IQV
26.37
Life Sciences Tools & Services Industry
- Max
- 117.96
- Q3
- 65.59
- Median
- 37.26
- Q1
- 27.51
- Min
- 1.73
In the lower quartile for the Life Sciences Tools & Services industry, IQV’s P/E Ratio of 26.37 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
RDY
18.29
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
RDY’s P/E Ratio of 18.29 is within the middle range for the Pharmaceuticals industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
IQV
2.08
Life Sciences Tools & Services Industry
- Max
- 12.46
- Q3
- 6.70
- Median
- 4.24
- Q1
- 2.68
- Min
- 0.73
In the lower quartile for the Life Sciences Tools & Services industry, IQV’s P/S Ratio of 2.08 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
RDY
3.10
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
RDY’s P/S Ratio of 3.10 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
IQV
4.72
Life Sciences Tools & Services Industry
- Max
- 7.99
- Q3
- 4.69
- Median
- 3.30
- Q1
- 1.88
- Min
- 1.02
IQV’s P/B Ratio of 4.72 is in the upper tier for the Life Sciences Tools & Services industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
RDY
2.84
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
RDY’s P/B Ratio of 2.84 is within the conventional range for the Pharmaceuticals industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | IQV | RDY |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 26.37 | 18.29 |
| Price-to-Sales Ratio (TTM) | 2.08 | 3.10 |
| Price-to-Book Ratio (MRQ) | 4.72 | 2.84 |
| Price-to-Free Cash Flow Ratio (TTM) | 16.23 | 86.35 |